Innate Immune Pathways in Atherosclerosis—From Signaling to Long-Term Epigenetic Reprogramming
Cells · 2023
DOI: 10.3390/cells12192359 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Arailym Aronova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilian-University (LMU), 80539 Munich, Germany. Hauptthemen laut MEDLINE: Atherosclerosis, Plaque, Atherosclerotic, Cardiovascular Diseases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Innate immune pathways play a crucial role in the development of atherosclerosis, from sensing initial danger signals to the long-term reprogramming of immune cells. Despite the success of lipid-lowering therapy, anti-hypertensive medications, and other measures in reducing complications associated with atherosclerosis, cardiovascular disease (CVD) remains the leading cause of death worldwide. Consequently, there is an urgent need to devise novel preventive and therapeutic strategies to alleviate the global burden of CVD. Extensive experimental research and epidemiological studies have demonstrated the dominant role of innate immune mechanisms in the progression of atherosclerosis. Recently, landmark trials including CANTOS, COLCOT, and LoDoCo2 have provided solid evidence demonstrating that targeting innate immune pathways can effectively reduce the risk of CVD. These groundbreaking trials mark a significant paradigm shift in the field and open new avenues for atheroprotective treatments. It is therefore crucial to comprehend the intricate interplay between innate immune pathways and atherosclerosis for the development of targeted therapeutic interventions. Additionally, unraveling the mechanisms underlying long-term reprogramming may offer novel strategies to reverse the pro-inflammatory phenotype of immune cells and restore immune homeostasis in atherosclerosis. In this review, we present an overview of the innate immune pathways implicated in atherosclerosis, with a specific focus on the signaling pathways driving chronic inflammation in atherosclerosis and the long-term reprogramming of immune cells within atherosclerotic plaque. Elucidating the molecular mechanisms governing these processes presents exciting opportunities for the development of a new class of immunotherapeutic approaches aimed at reducing inflammation and promoting plaque stability. By addressing these aspects, we can potentially revolutionize the management of atherosclerosis and its associated cardiovascular complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilian-University (LMU), 80539 Munich, Germany.
ORCID-Profile: Arailym Aronova, Yaw Asare
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Aronova, A., Tosato, F., Naser, N., & Asare, Y. (2023). Innate Immune Pathways in Atherosclerosis—From Signaling to Long-Term Epigenetic Reprogramming. Cells. https://doi.org/10.3390/cells12192359
Vancouver
Aronova A, Tosato F, Naser N, Asare Y. Innate Immune Pathways in Atherosclerosis—From Signaling to Long-Term Epigenetic Reprogramming. Cells. 2023. doi:10.3390/cells12192359
BibTeX
@article{Aronova2023,
author = {Aronova, Arailym and Tosato, Federica and Naser, Nawraa and Asare, Yaw},
title = {Innate Immune Pathways in Atherosclerosis—From Signaling to Long-Term Epigenetic Reprogramming},
journal = {Cells},
year = {2023},
doi = {10.3390/cells12192359}
}
EUVIMED